This guidance has been replaced by CG178 Psychosis and schizophrenia in adults
This guidance updates and replaces NICE technology appraisal 43 (published in June 2002).
The Guideline Development Group (GDG) oversees the development process. See below for a list of GDG members.
The NCCs may make a focussed call for evidence on specific clinical questions or subquestions, after it has done initial searches. It will be able to make a call at any point during development of the guideline, and stakeholders will usually be given 4 weeks to respond. The NCC will approach all registered stakeholders for this evidence. The NCC may not issue any calls for evidence for a guideline if the Guideline Development Group (GDG) feels it is not necessary.
In addition, the NCCs will accept relevant confidential data for consideration by the GDG.
The scope (see link below) defines what aspects of care are covered by the guideline and to whom it applies.
Comments that were made by stakeholders during the consultation on the scope can be seen in the scope consultation table (see link below).